Xultophy: first insulin/incretin mimetic combination launched

Xultophy is a prefilled pen containing a fixed-ratio combination of insulin degludec and liraglutide, licensed for the treatment of type II diabetes in combination with oral hypoglycaemics.

by
Xultophy is the first product to combine a basal insulin and an incretin mimetic to allow administration of both drugs in a single subcutaneous injection
Xultophy is the first product to combine a basal insulin and an incretin mimetic to allow administration of both drugs in a single subcutaneous injection

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package